Patients with acute or chronic coronary syndrome (ACS or CCS) are at increased risks of ischemic events, if they have the ischemic risk factors which include older age (i.e. >65 years), chronic kidney disease (CKD), diabetes mellitus (DM), prior myocardial infarction (MI), and multi-vessel disease, etc. There has been evidence supporting the long-term dual antiplatelet therapy (DAPT) with ticagrelor in addition to aspirin. However, its use among high-risk patients in real-life practice remains suboptimal.

This survey aims to seek your experiences and opinions in optimizing antiplatelet strategy for patients with ACS or CCS. It only takes about 5 minutes to complete the survey, which is duly voluntary. Your participation is much appreciated!.

By completing this survey, you acknowledge that all information you provided will be used in analysis and publication for medical education purpose only. All personal data (i.e., information that would let someone identify you) will be kept confidential and secure.

Please visit contactazmedical.astrazeneca.com for (1) enquiring Medical Information (MI), (2) reporting Individual Case Safety Report (ICSR) and/or (3) reporting Product Quality Complaint (PQC) to AstraZeneca Hong Kong Limited.

如向阿斯利康香港有限公司(1) 查詢醫藥資訊、(2) 報告個別藥物的安全性及/或(3) 投訴產品品質，請瀏覽網頁：contactazmedical.astrazeneca.com。

Approval code and date – TBC

1.   Which of the followings are the most important ischemic risk factors for ACS patients? (Please rank 1-5, 1 = most important; 5 = least important)

2.  With how many of the above risk factors will you prescribe a potent P2Y12 inhibitor?

3.  In the above cases, which P2Y12 inhibitor will you prescribe?

4.   If the above case undergoes percutaneous coronary intervention (PCI), which treatment duration would you preferred following PCI?

4.   If the above case undergoes percutaneous coronary intervention (PCI), which treatment duration would you preferred following PCI?

6.   Are you working in the public or private sector?